Article
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Molecular systems biology - 23 Dec 2014
Smit Marjon A, Maddalo Gianluca, Greig Kylie, Raaijmakers Linsey M, Possik Patricia A, van Breukelen Bas, Cappadona Salvatore, Heck Albert J R, Altelaar A F Maarten, Peeper Daniel S
Abstract excerpt
Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibition sensitizes melanoma cells to BRAF inhibition. We found many proteins to be induced upon PLX4720 (BRAF inhibitor)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.